EP2035005A4 - Therapy using cytokine inhibitors - Google Patents

Therapy using cytokine inhibitors

Info

Publication number
EP2035005A4
EP2035005A4 EP07798190A EP07798190A EP2035005A4 EP 2035005 A4 EP2035005 A4 EP 2035005A4 EP 07798190 A EP07798190 A EP 07798190A EP 07798190 A EP07798190 A EP 07798190A EP 2035005 A4 EP2035005 A4 EP 2035005A4
Authority
EP
European Patent Office
Prior art keywords
therapy
cytokine inhibitors
cytokine
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07798190A
Other languages
German (de)
French (fr)
Other versions
EP2035005A2 (en
Inventor
Constance A Crowley
Nancy G J Delaet
Justin Ernst
Carrie Gail Grove
Bonnie Hepburn
Bernard King
Christopher J Larson
Stephen Miller
Kent Pryor
Lewis J Shuster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemia Inc
Original Assignee
Kemia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia Inc filed Critical Kemia Inc
Publication of EP2035005A2 publication Critical patent/EP2035005A2/en
Publication of EP2035005A4 publication Critical patent/EP2035005A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP07798190A 2006-06-09 2007-06-06 Therapy using cytokine inhibitors Withdrawn EP2035005A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81226806P 2006-06-09 2006-06-09
US83307806P 2006-07-24 2006-07-24
US83527006P 2006-08-03 2006-08-03
PCT/US2007/070547 WO2007146712A2 (en) 2006-06-09 2007-06-06 Therapy using cytokine inhibitors

Publications (2)

Publication Number Publication Date
EP2035005A2 EP2035005A2 (en) 2009-03-18
EP2035005A4 true EP2035005A4 (en) 2011-07-06

Family

ID=38832677

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07798190A Withdrawn EP2035005A4 (en) 2006-06-09 2007-06-06 Therapy using cytokine inhibitors

Country Status (8)

Country Link
EP (1) EP2035005A4 (en)
AR (1) AR061273A1 (en)
AU (1) AU2007257959A1 (en)
CA (1) CA2691214A1 (en)
CL (1) CL2007001670A1 (en)
PE (1) PE20080935A1 (en)
TW (1) TW200814998A (en)
WO (1) WO2007146712A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641880C (en) 2006-02-10 2014-09-09 Summit Corporation Plc Treatment of duchenne muscular dystrophy
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US7919490B2 (en) 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200837064A (en) 2006-10-04 2008-09-16 Pharmacopeia Inc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US8440832B2 (en) * 2007-07-13 2013-05-14 Board Of Regents, The University Of Texas System Heterocyclic modulators of cannabinoid receptors
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
CN102099036B (en) 2008-06-03 2015-05-27 英特芒尼公司 Compounds and methods for treating inflammatory and fibrotic disorders
WO2010053861A2 (en) * 2008-11-07 2010-05-14 H. Lundbeck A/S Biologically active amides
WO2010141932A1 (en) 2009-06-05 2010-12-09 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
WO2011063076A1 (en) * 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
EP2633857B1 (en) * 2009-12-23 2015-08-12 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN102918034B (en) 2010-03-30 2015-06-03 维颂公司 Polysubstituted aromatic compounds as inhibitors of thrombin
ES2608474T3 (en) 2010-04-22 2017-04-11 Vertex Pharmaceuticals Incorporated Production process of indole compounds cycloalkylcarboxamido
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
DE202012012955U1 (en) 2011-10-21 2014-07-14 Abbvie Inc. A combination of at least two direct-acting antiviral agents (DAAs) for use in the treatment of HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
LT2968297T (en) 2013-03-15 2019-01-10 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
MX382781B (en) 2014-04-02 2025-03-13 Intermune Inc ANTI-FIBROTIC PYRIDINONES.
ES2885181T3 (en) 2014-04-15 2021-12-13 Vertex Pharma Pharmaceutical compositions for the treatment of diseases mediated by the transmembrane conductance regulator of cystic fibrosis
CN106687445A (en) 2014-09-17 2017-05-17 维颂公司 Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
EP3230279A1 (en) 2014-12-10 2017-10-18 Massachusetts Institute of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
RU2017131562A (en) 2015-02-27 2019-03-27 Версеон Корпорейшн SUBSTITUTED PYRAZOLIC COMPOUNDS AS SERINE PROTEASES INHIBITORS
EP3307273B1 (en) * 2015-06-12 2020-12-09 University of Greenwich Triazine derivatives as interferon-gamma inhibitors
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
CN109071516B (en) 2015-12-15 2021-08-31 阿斯利康(瑞典)有限公司 novel compound
MA44075A (en) 2015-12-17 2021-05-19 Incyte Corp N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN / PROTEIN PD-1 / PD-L1 INTERACTIONS
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
KR20180107261A (en) 2016-02-16 2018-10-01 메사추세츠 인스티튜트 오브 테크놀로지 MAX binders as Myc modifiers and their uses
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS
AR108396A1 (en) 2016-05-06 2018-08-15 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2866883T3 (en) 2016-06-08 2021-10-20 Support Venture Gmbh Pharmaceutical combinations for the treatment of cancer
HUE060256T2 (en) 2016-06-20 2023-02-28 Incyte Corp Heterocyclic compounds as immunomodulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
JP6883653B2 (en) 2016-12-20 2021-06-09 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Amino-triazolopyridine compounds and their use in the treatment of cancer
JP7101678B2 (en) 2016-12-22 2022-07-15 インサイト・コーポレイション Heterocyclic compounds as immunomodulators
LT3558990T (en) 2016-12-22 2022-12-27 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2874756T3 (en) 2016-12-22 2021-11-05 Incyte Corp Triazolo [1,5-A] pyridine derivatives as immunomodulators
US11242327B2 (en) * 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN111646986B (en) * 2017-09-13 2022-03-25 厦门稀土材料研究所 Nicotinic acid derivative and preparation method and application thereof
BR112020006677A2 (en) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. use of p38 inhibitors to reduce dux4 expression
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019126731A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
SMT202500157T1 (en) 2018-03-30 2025-05-12 Incyte Corp Heterocyclic compounds as immunomodulators
HUE061503T2 (en) 2018-05-11 2023-07-28 Incyte Corp Tetrahydroimidazo[4,5-C]pyridine derivatives as PD-L1 immunomodulators
PT3802517T (en) 2018-06-07 2023-03-20 Idorsia Pharmaceuticals Ltd Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis
KR20250161056A (en) * 2018-09-13 2025-11-14 에이리온 테라퓨틱스, 인코포레이티드 Uses of plasminogen activator inhibitor 1(pai-1) inhibitors
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020113088A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
CN111825605B (en) * 2019-04-19 2023-03-31 中国科学院上海药物研究所 Aryl ketone amide compound and preparation method and application thereof
TW202112767A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
AR119162A1 (en) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd PYRIDIN-3-YL DERIVATIVES
JP7665593B2 (en) 2019-08-09 2025-04-21 インサイト・コーポレイション Salts of PD-1/PD-L1 inhibitors
PE20221038A1 (en) 2019-09-30 2022-06-17 Incyte Corp PYRIDO[3,2-D] PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS
WO2021092240A1 (en) * 2019-11-05 2021-05-14 Dermira, Inc. Mrgprx2 antagonists for the treatment of inflammatory disorders
CA3160131A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
JP7665619B2 (en) 2019-12-04 2025-04-21 イドルシア・ファーマシューティカルズ・リミテッド Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
BR112022010924A2 (en) 2019-12-06 2022-09-06 Vertex Pharma SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATION
CR20230230A (en) 2020-11-06 2023-07-27 Incyte Corp PROCESS FOR MAKING A PD-1/PDL1 INHIBITOR AND SALTS AND CRYSTALLINE FORMS THEREOF
TW202233615A (en) 2020-11-06 2022-09-01 美商英塞特公司 Crystalline form of a pd-1/pd-l1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
CN113209112B (en) * 2021-02-06 2021-12-24 广州市朝利良生物科技有限公司 Novel coronavirus resistant medicine based on ACE2 and S protein binding target and application thereof
SMT202500481T1 (en) 2021-06-04 2026-01-12 Vertex Pharma N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
KR20250010152A (en) 2022-02-14 2025-01-20 액센트 테라퓨틱스, 인크. Inhibitors of RNA helicase DHX9 and uses thereof
WO2024059220A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,5 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
CN118496159B (en) * 2024-07-18 2024-09-24 广州医科大学附属市八医院 Application of compound in preparation of medicine with liver fibrosis preventing and/or treating effect

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008868A1 (en) * 2001-05-16 2003-01-09 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008868A1 (en) * 2001-05-16 2003-01-09 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
US20100273797A1 (en) * 2003-09-11 2010-10-28 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof

Also Published As

Publication number Publication date
WO2007146712A2 (en) 2007-12-21
CA2691214A1 (en) 2007-12-21
CL2007001670A1 (en) 2008-01-18
PE20080935A1 (en) 2008-08-02
AR061273A1 (en) 2008-08-13
EP2035005A2 (en) 2009-03-18
TW200814998A (en) 2008-04-01
WO2007146712A3 (en) 2008-11-27
AU2007257959A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
EP2035005A4 (en) Therapy using cytokine inhibitors
EP2214669A4 (en) Cytokine inhibitors
EP2026843A4 (en) Therapeutic uses of inhibitors of rtp801l
GB2436010B (en) Therapy device
IL196559A0 (en) Combination therapy
GB0609492D0 (en) Therapeutic agents
SI2338487T1 (en) Combination therapy with PARP inhibitors
IL179398A0 (en) Dpp-ib inhibitors
GB0608928D0 (en) Therapeutic agents
IL193674A0 (en) Therapeutic piperazines as pde4 inhibitors
IL197818A0 (en) Multiple sclerosis therapy
GB0601962D0 (en) Therapeutic agents
IL196556A0 (en) Combination therapy
SI2094702T1 (en) Viral inhibitors
EP2054061A4 (en) Combination therapy
IL198026A0 (en) Sequential combination therapy
ZA200902203B (en) Combination therapy
EP2131858A4 (en) P38 inhibitors
GB0611152D0 (en) Therapeutic agents
GB0421355D0 (en) Inhibitors
GB0620059D0 (en) Therapeutic agents
GB0620818D0 (en) Therapeutic agents
EP1816194A4 (en) Cancer-cell-specific proliferation inhibitors
GB0609676D0 (en) Therapeutic agents
GB0421356D0 (en) Inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090108

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SHUSTER, LEWIS, J.

Inventor name: PRYOR, KENT

Inventor name: MILLER, STEPHEN

Inventor name: LARSON, CHRISTOPHER, J.

Inventor name: KING, BERNARD

Inventor name: HEPBURN, BONNIE

Inventor name: GROVE, CARRIE, GAIL

Inventor name: ERNST, JUSTIN

Inventor name: DELAET, NANCY G., J.

Inventor name: CROWLEY, CONSTANCE, A.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110607

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120105